2/5
08:30 am
allo
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Medium
Report
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
1/29
11:12 pm
allo
??·?????????????????2035????1,831????????????????? [CNET News]
High
Report
??·?????????????????2035????1,831????????????????? [CNET News]
1/9
11:12 am
allo
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? [Yahoo! Finance]
Medium
Report
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? [Yahoo! Finance]
1/9
08:42 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "mkt outperform" rating. They now have a $5.00 price target on the stock.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "mkt outperform" rating. They now have a $5.00 price target on the stock.
1/9
07:00 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
1/9
06:10 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/8
09:06 am
allo
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T [Yahoo! Finance]
Low
Report
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T [Yahoo! Finance]
1/8
08:30 am
allo
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
Low
Report
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
1/7
09:07 am
allo
Allogene Therapeutics (NASDAQ:ALLO) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
12/15
06:21 pm
allo
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis [Yahoo! Finance]
12/15
05:39 pm
allo
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Medium
Report
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis